These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1303 related articles for article (PubMed ID: 32638404)

  • 41. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.
    Aichen Z; Kun W; Xiaochun S; Lingling T
    Apoptosis; 2021 Jun; 26(5-6):348-360. PubMed ID: 33974163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
    Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
    Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of lncRNAHCP5/microRNA-525-5p/PRC1 crosstalk in the malignant behaviors of ovarian cancer cells.
    Wang L; He M; Fu L; Jin Y
    Exp Cell Res; 2020 Sep; 394(1):112129. PubMed ID: 32511950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long non-coding RNA PRNCR1 modulates non-small cell lung cancer cell proliferation, apoptosis, migration, invasion, and EMT through PRNCR1/miR-126-5p/MTDH axis.
    Guo R; Hu T; Liu Y; He Y; Cao Y
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 31912882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis.
    Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N
    Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linc-PINT acted as a tumor suppressor by sponging miR-543 and miR-576-5p in esophageal cancer.
    Zhang L; Chen J; Wang L; Chen L; Du Z; Zhu L; Cui M; Zhang M; Song L
    J Cell Biochem; 2019 Dec; 120(12):19345-19357. PubMed ID: 31464068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LINC-PINT Suppresses the Aggressiveness of Thyroid Cancer by Downregulating miR-767-5p to Induce TET2 Expression.
    Jia M; Li Z; Pan M; Tao M; Wang J; Lu X
    Mol Ther Nucleic Acids; 2020 Dec; 22():319-328. PubMed ID: 33230437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance through miR-425-5p/PTCH1/SHH axis.
    Yuan Z; Xiu C; Liu D; Zhou G; Yang H; Pei R; Ding C; Cui X; Sun J; Song K
    J Cell Physiol; 2019 Dec; 234(12):23111-23122. PubMed ID: 31131448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC.
    Li Z; Wu G; Li J; Wang Y; Ju X; Jiang W
    BMC Cancer; 2020 Apr; 20(1):282. PubMed ID: 32252678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA-139-5p Inhibits Cell Proliferation and Invasion by Targeting RHO-Associated Coiled-Coil-Containing Protein Kinase 2 in Ovarian Cancer.
    Wang Y; Li J; Xu C; Zhang X
    Oncol Res; 2018 Apr; 26(3):411-420. PubMed ID: 28653604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p.
    Yao J; Fu J; Liu Y; Qu W; Wang G; Yan Z
    Ann Hepatol; 2021; 23():100297. PubMed ID: 33346094
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-coding RNA LOXL1-AS1 exhibits oncogenic activity in ovarian cancer via regulation of miR-18b-5p/VMA21 axis.
    Xue F; Xu YH; Shen CC; Qin ZL; Zhou HB
    Biomed Pharmacother; 2020 May; 125():109568. PubMed ID: 32058209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The lncRNA SNHG15/miR-18a-5p axis promotes cell proliferation in ovarian cancer through activating Akt/mTOR signaling pathway.
    Zhang J; Wang L; Jiang J; Qiao Z
    J Cell Biochem; 2020 Dec; 121(12):4699-4710. PubMed ID: 33135285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway.
    Du W; Feng Z; Sun Q
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):198-202. PubMed ID: 30442370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LncRNA-MSC-AS1 inhibits the ovarian cancer progression by targeting miR-425-5p.
    Zhao Y; Yuan D; Zhu D; Xu T; Huang A; Jiang L; Liu C; Qian H; Bu X
    J Ovarian Res; 2021 Aug; 14(1):109. PubMed ID: 34454554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1.
    Han S; Zhu J; Zhang Y
    Med Sci Monit Basic Res; 2018 Feb; 24():40-46. PubMed ID: 29445078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinoma.
    Zhou Y; Fan RG; Qin CL; Jia J; Wu XD; Zha WZ
    Genomics; 2019 Dec; 111(6):1862-1872. PubMed ID: 30543848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LINC-DUBR Suppresses Malignant Progression of Ovarian Cancer by Downregulating miR-107 to Induce SMAC Expression.
    Han Z; Li D; Yang Y; Zhang H
    J Healthc Eng; 2022; 2022():4535655. PubMed ID: 35281523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. lncRNA AC005224.4/miR-140-3p/SNAI2 regulating axis facilitates the invasion and metastasis of ovarian cancer through epithelial-mesenchymal transition.
    Xiong T; Wang Y; Zhang Y; Yuan J; Zhu C; Jiang W
    Chin Med J (Engl); 2023 May; 136(9):1098-1110. PubMed ID: 36939239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), Negatively Regulated by microRNA (miR)-195-5p, Accelerates the Malignant Progression of Ovarian Cancer.
    Wu D; Liu C; Hong L
    Mol Biotechnol; 2021 Dec; 63(12):1235-1243. PubMed ID: 34338995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.